Earnings Releases·Nov 12, 2026, 4:17 PM ET

ProMIS Neurosciences — Third Quarter 2026 Earnings Summary

Cash position increased to $44.1 million as of September 30, 2026, from $6.1 million at year-end 2025, driven by $70.1 million in net proceeds from a January 2026 private placement, resulting in positive shareholders' equity of $41.8 million.
Net loss narrowed to $8.2 million ($0.89 per share) for the three months ended September 30, 2026, compared to $11.6 million ($5.93 per share) in the prior year period, primarily due to a 32% reduction in R&D expenses as the PRECISE-AD trial neared patient visit completion.
The PRECISE-AD Phase 1b trial remains on track for unblinded 12-month topline data in Q1 2027, with interim data showing no ARIA-E across all APOE genotypes and significant biomarker reductions; existing cash is expected to fund operations through 2027.
Strategic developments include the appointment of Ivana Rubino as Chief Commercial Officer, the selection of a subcutaneous PMN310 formulation for future development, and plans to initiate a registrational study for this formulation toward the end of 2027 subject to FDA feedback.